CH Biotech R&D Co., Ltd. (6534.TW)
TWD 80.6
(-0.49%)
TWD 80.6
(-0.49%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 659.15 Million | 698.96 Million | 264.35 Million | 232.9 Million | - |
| Net Income | 578.93 Million | 565.79 Million | 359.65 Million | 127.39 Million | - |
| Depreciation & Amortization | 165.81 Million | 139.68 Million | 96.65 Million | 98.19 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 1.24 Million | - | - | - | - |
| Change in working capital | -14.14 Million | 81.39 Million | -164.73 Million | 23.64 Million | - |
| Other non-cash items | 4.71 Million | 13.89 Million | 13.38 Million | 22.28 Million | - |
| Investing Cash Flow | -142.89 Million | -117.22 Million | -44.75 Million | -108.62 Million | - |
| Investments in PPE | -116.26 Million | -117.61 Million | -71.92 Million | -108.75 Million | - |
| Acquisitions | -29.4 Million | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | 164 Thousand | -841 Thousand | 26.94 Million | 87 Thousand | - |
| Financing Cash Flow | -106.6 Million | -375.37 Million | -222.05 Million | -81.73 Million | - |
| Debt repayment | -50 Million | -229.34 Million | -164.39 Million | -20.27 Million | - |
| Dividends payments | -473.76 Million | -126.63 Million | -42.21 Million | -88.44 Million | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 442.25 Million | - | - | - | - |
| Other Financing Activities | -25.09 Million | - | - | - | - |
| Accounts receivables | -72.28 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | 52.96 Million | -76.48 Million | -65.27 Million | 10.51 Million | - |
| Other working capital | 5.17 Million | - | - | - | - |
| Cash at beginning of period | 530.02 Million | 321.01 Million | 324.01 Million | 281.98 Million | - |
| Cash at end of period | 939.93 Million | 530.02 Million | 321.01 Million | 324.01 Million | - |
| Capital Expenditure | -116.26 Million | -117.61 Million | -71.92 Million | -108.75 Million | - |
| Effect of forex changes on cash | 245 Thousand | 2.64 Million | -548 Thousand | -516 Thousand | - |
| Net cash flow / Change in cash | 409.9 Million | 209.01 Million | -2.99 Million | 42.02 Million | - |
| Free Cash Flow | 542.88 Million | 581.35 Million | 192.43 Million | 124.15 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 159.87 Million | 522.99 Million | 578.93 Million | -77.91 Million | -57.7 Million | 233.72 Million |
| Depreciation & Amortization | 46.52 Million | 45.83 Million | 165.81 Million | 44.47 Million | 41.56 Million | 40.32 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 1.24 Million | - | - | - |
| Change in working capital | 358.24 Million | -330.09 Million | -14.14 Million | -59.69 Million | 96.02 Million | 256.64 Million |
| Other non-cash items | -2.67 Million | -535 Thousand | 4.71 Million | 3.67 Million | -2.43 Million | 2.7 Million |
| Investing Cash Flow | -52.98 Million | -439.46 Million | -142.89 Million | -51.71 Million | -44.7 Million | -20.76 Million |
| Investments in PPE | -49.89 Million | -437.5 Million | -116.26 Million | -24.58 Million | -44.6 Million | -20.71 Million |
| Acquisitions | -3.54 Million | - | -29.4 Million | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 451 Thousand | -1.95 Million | 164 Thousand | 28 Thousand | -92 Thousand | -49 Thousand |
| Financing Cash Flow | -436.1 Million | 121.42 Million | -106.6 Million | 398.4 Million | -56.52 Million | -412.82 Million |
| Debt repayment | -112.91 Million | -127.7 Million | -50 Million | -60 Million | -50 Million | -30 Million |
| Dividends payments | - | - | -473.76 Million | -97.08 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 442.25 Million | - | - | - |
| Other Financing Activities | 3000.00 | 159 Thousand | - | - | - | - |
| Accounts receivables | 328.01 Million | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 27.47 Million | 31.97 Million | 52.96 Million | 598 Thousand | -33.12 Million | 39.84 Million |
| Other working capital | 2.75 Million | - | - | - | - | - |
| Cash at beginning of period | 862.61 Million | 939.93 Million | 530.02 Million | 684.26 Million | 705.94 Million | 680.49 Million |
| Cash at end of period | 818.1 Million | 862.61 Million | 939.93 Million | 939.93 Million | 684.26 Million | 705.94 Million |
| Capital Expenditure | -49.89 Million | -437.5 Million | -116.26 Million | -24.58 Million | -44.6 Million | -20.71 Million |
| Effect of forex changes on cash | 247 Thousand | 1.29 Million | 245 Thousand | -1.23 Million | 522 Thousand | 1.15 Million |
| Net cash flow / Change in cash | -44.51 Million | -77.31 Million | 409.9 Million | 255.66 Million | -21.67 Million | 25.44 Million |
| Free Cash Flow | 394.43 Million | -198.07 Million | 542.88 Million | -114.37 Million | 34.42 Million | 437.16 Million |
DXI
RCGH
1341
5267
APR-UN
APEI